What is the recommended artesunate dosing regimen for severe Plasmodium falciparum malaria in a 70 kg adult (including repeat doses and transition to oral therapy) and how should it be adjusted for children?

Artesunate Dosing for Severe Malaria

For a 70 kg adult with severe Plasmodium falciparum malaria, administer intravenous artesunate at 2.4 mg/kg (168 mg) at 0,12, and 24 hours, then continue 2.4 mg/kg daily; transition to oral artemisinin-based combination therapy when the patient can tolerate oral medication AND parasitemia is <1%. 1

Adult Dosing Algorithm

Initial IV Phase

• Dose: 2.4 mg/kg IV at 0,12, and 24 hours (three doses in first 24 hours)
• For 70 kg patient: 168 mg per dose
• After 24 hours: Continue 2.4 mg/kg IV once daily

Transition Criteria to Oral Therapy

You must meet BOTH conditions:

1. Patient able to tolerate oral medication
2. Parasite density <1%

If either condition is NOT met: Continue IV artesunate 2.4 mg/kg daily for up to 7 days total 1

Oral Completion Phase

Once transition criteria met, complete treatment with a full course of:

• First choice: Artemether-lumefantrine (24 tablets over 72 hours for >35 kg) 1
• Alternative: Dihydroartemisinin-piperaquine (3-4 tablets daily for 3 days based on weight) 1

Pediatric Dosing

Children should receive the SAME 2.4 mg/kg dosing regimen as adults - this is critical and evidence-based. 1

Important Pediatric Controversy

Recent evidence strongly supports maintaining 2.4 mg/kg in children rather than reducing the dose. A 2023 pharmacokinetic study demonstrated that younger children given lower doses fail to achieve adequate drug exposures compared to older children, creating risk of treatment failure in this rapidly lethal infection 2. The FDA's suggestion to lower pediatric doses has been challenged by this evidence, which showed "the majority of younger children given the lower 2.4 mg/kg dose...do not reach the same drug exposures as older children above 20 kg" 2.

Do NOT reduce the dose for children <20 kg - use 2.4 mg/kg regardless of age or weight.

Critical Safety Monitoring

Post-Artesunate Delayed Hemolysis (PADH)

• Monitor hemoglobin weekly for 4 weeks after treatment completion
• Risk is higher with hyperparasitemia (>10% parasitemia)
• Can occur even after successful parasite clearance 1

Liver Function Tests

• Artesunate itself has minimal hepatotoxicity
• Monitor ALT/AST if transitioning to artemether-lumefantrine or other ACTs
• Pyronaridine-containing regimens significantly increase ALT (RR 3.59) and AST (RR 2.22) risk 3

Common Pitfalls to Avoid

1. Premature transition to oral therapy: Do not switch before BOTH criteria are met (oral tolerance AND <1% parasitemia). Patients with >1% parasitemia need continued IV therapy even if clinically improved 1

2. Underdosing children: Resist any temptation to reduce doses in young children - they require the full 2.4 mg/kg to achieve therapeutic exposures 2

3. Inadequate parasite monitoring: Check parasitemia at 12-24 hour intervals initially. Delayed parasite clearance may indicate partial artemisinin resistance, particularly in patients from Southeast Asia or East Africa 4

4. Missing PADH: Hemolysis can occur 1-3 weeks post-treatment. Schedule follow-up hemoglobin checks at weeks 1,2,3, and 4 1

Evidence Strength

The 2.4 mg/kg dosing is supported by high-quality 2024 guidelines from Clinical Microbiology and Infection 1, which represent the most current expert consensus for non-endemic settings. The landmark SEAQUAMAT trial demonstrated 34.7% mortality reduction with artesunate versus quinine (15% vs 22%, p=0.0002) 5, establishing artesunate as first-line therapy. This mortality benefit is the primary reason artesunate is universally recommended over quinine for severe malaria 1, 5.